In the changing health-care environment where improving patient outcomes, saving costs and providing patient-centric care is king, life-science and medtech companies with a single focus on developing products risk being outpaced and outsmarted by the rising crop of tech companies that offer a broad spectrum of data-driven health services, according to Ernst & Young's new report, "Progressions 2018 Life Sciences 4:0: Securing Value Through Data-Driven Platforms."
The report states that more than 75% of life-science Fortune 500 companies may fall out of the ranking by 2023 if they don't look beyond developing novel drugs and devices,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?